Acquisition - February 6, 2024
Novo Holdings to acquire Catalent
Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at USD 16.5 billion on an enterprise value basis. Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, will acquire all outstanding shares of CDMO Catalent for USD 63.50 per share […]
Agreement - February 5, 2024
Biovian and 3P Biopharmaceuticals join forces
The two biologics Contract Development and Manufacturing Organizations (CDMOs), have announced their combination. Backed by their common shareholder, Keensight Capital, the combination of Biovian and 3P extends the group’s value proposition to address complex customer needs across the entire development cycle, the companies state. Keensight Capital will continue to help the Group strengthen its position […]
Agreement - February 4, 2024
Orion enters licensing agreement with Newel Health
Orion Corporation and Newel Health have entered into a license agreement regarding ODD-403, a digital therapeutic (DTx) developed by Orion for patients suffering from chronic pain and particularly from fear of movement and re-injury. Under the terms of the agreement, Newel will have the exclusive global rights to develop, manufacture and commercialize ODD-403. Orion is […]
Pharma Business - February 2, 2024
AstraZeneca’s Enhertu granted Priority Review in the US
If approved, AstraZeneca and Daiichi Sankyo’s Enhertu will potentially be the first HER2-directed treatment and antibody drug conjugate to receive a tumor-agnostic indication. AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-positive […]
Business Award - January 31, 2024
Genovis wins SwedenBIO Award
Genovis’ CEO, Fredrik Olsson, received the award in a prize ceremony during SwedenBIO Summit at Grand Hôtel in Stockholm on 30th January. High-quality research, global presence and humor were some of the positive words describing the company Genovis, which claimed this year’s SwedenBIO Award. “Life science is a tough industry where success doesn’t come easy, […]
Business article - January 30, 2024
SwedenBIO’s Life Science Barometer has been released
The Life Science Barometer is an annual survey with the aim of offering unique insights and fresh statistics about the Swedish life science industry. A record number of companies participated in the survey for this year’s edition, which makes the report SwedenBIO’s most comprehensive to date. The report is produced by SwedenBIO in collaboration with […]
